Endo International (NASDAQ:ENDP) (TSE:ENL) was upgraded by analysts at Canaccord Genuity to a “buy” rating in a research note issued on Friday. The firm presently has a $20.00 target price on the stock. Canaccord Genuity’s price objective points to a potential upside of 51.63% from the stock’s current price.
A number of other research analysts have also recently commented on ENDP. ValuEngine cut shares of Endo International from a “hold” rating to a “sell” rating in a research report on Thursday. Cowen reiterated a “hold” rating and set a $9.00 price target on shares of Endo International in a research report on Friday. Deutsche Bank set a $11.00 price target on shares of Endo International and gave the company a “buy” rating in a research report on Wednesday, July 18th. Stifel Nicolaus increased their price target on shares of Endo International from $10.00 to $17.00 and gave the company a “hold” rating in a research report on Thursday, August 9th. Finally, BMO Capital Markets increased their price target on shares of Endo International from $9.00 to $16.00 and gave the company a “market perform” rating in a research report on Friday, August 10th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Endo International presently has a consensus rating of “Hold” and an average price target of $14.97.
ENDP stock opened at $13.19 on Friday. The company has a market capitalization of $3.84 billion, a P/E ratio of 3.43, a P/E/G ratio of 1.65 and a beta of 0.65. Endo International has a 1-year low of $5.27 and a 1-year high of $18.50.
In other news, Director Roger H. Kimmel sold 26,074 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total value of $414,576.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.80% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp grew its holdings in shares of Endo International by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock worth $23,074,000 after purchasing an additional 284,599 shares during the last quarter. Diamond Hill Capital Management Inc. grew its holdings in shares of Endo International by 1.0% in the second quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock worth $10,375,000 after purchasing an additional 10,600 shares during the last quarter. Schroder Investment Management Group lifted its stake in Endo International by 78.1% in the second quarter. Schroder Investment Management Group now owns 747,571 shares of the company’s stock worth $7,349,000 after acquiring an additional 327,775 shares during the period. River & Mercantile Asset Management LLP lifted its stake in Endo International by 18.6% in the second quarter. River & Mercantile Asset Management LLP now owns 554,835 shares of the company’s stock worth $5,229,000 after acquiring an additional 87,102 shares during the period. Finally, Alps Advisors Inc. lifted its stake in Endo International by 9.6% in the second quarter. Alps Advisors Inc. now owns 501,708 shares of the company’s stock worth $4,731,000 after acquiring an additional 43,791 shares during the period. Hedge funds and other institutional investors own 98.43% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.